BB
Therapeutic Areas
Rocket Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KRESLADI™ (RP-L201) | Severe Leukocyte Adhesion Deficiency-I (LAD-I) | Approved |
| RP-A501 | Danon Disease | Phase 2 |
| RP-L102 | Fanconi Anemia (FA) complementation group A | Phase 2 |
| RP-L301 | Pyruvate Kinase Deficiency (PKD) | Phase 1/2 |
| RP-A601 | PKP2-arrhythmogenic cardiomyopathy | Preclinical |